Boehringer Ingelheim USA Corporation

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.

The global psoriasis drug market is valued at US$ 14.08 billion in 2024, projected to grow at a CAGR of 6.9% to US$ 27.57 billion by 2034. Factors like smoking, alcohol, and cold temperatures increase psoriasis risk, driving market growth, especially in cold climates like the U.S. Key players include Amgen, Eli Lilly, and Novartis, focusing on strategic partnerships and product innovations. Corticosteroids are widely used for psoriasis treatment, prompting increased production by manufacturers.

Boehringer Ingelheim launches Eurican L4 vaccine in France to protect dogs against leptospirosis, targeting four key Leptospira serogroups. The vaccine offers effective immunity and is available for puppies from seven weeks old, with a booster and yearly vaccination required. The company aims to address the increasing threat of leptospirosis due to climate change and urbanization.

Mirikizumab (Omvoh) showed improved outcomes in Crohn's disease patients with previous standard therapy failure, with 38% meeting composite endpoint of PRO clinical response at week 12 and endoscopic response at week 52 vs. 9% on placebo (P<0.0001). Mirikizumab also met primary endpoint of PRO clinical response at week 12 and CDAI clinical remission at week 52 in 45.4% vs. 19.6% on placebo (P<0.0001). The study highlights IL-23's role in Crohn's disease pathogenesis and suggests mirikizumab's favorable benefit-risk profile.

Boehringer Ingelheim launches a next-gen Marek’s disease vaccine in India, offering enhanced protection through a controlled attenuation process. This vaccine targets the most virulent strains, aiming to reduce outbreaks, promote flock health, and support food security. It provides early and long-lasting immunity, crucial for India's expanding poultry industry.

Boehringer Ingelheim launches VETMEDIN Solution, the first FDA-approved oral solution for managing CHF in dogs due to MMVD or DCM. This liquid version offers a convenient option for pet owners, providing the same benefits as VETMEDIN chewable tablets, which have extended dogs' lives by over 1 million years globally.

Semaglutide and GLP-1 drugs, including those by Novo Nordisk® and Eli Lilly™, are being investigated for applications in heart disease, Alzheimer’s, liver disease, and more, with expected revenues to exceed $100 billion annually. These drugs, initially for diabetes and weight loss, have shown efficacy in reducing cardiovascular risks, treating sleep apnea, knee pain, and potentially Alzheimer’s and dementia. Lexaria Bioscience Corp. is researching its DehydraTECH technology to enhance drug delivery, aiming to capitalize on this significant pharmaceutical development.

DelveInsight's report on Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034 details the market size, emerging therapies, and key companies like Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma, Gilead Sciences, Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others. The market size in 7MM was ~USD 9,000 million in 2023, expected to increase by 2034, with key therapies like ENTYVIO, STELARA, VELSIPITY, Zeposia, LY-3074828, RHB-104, and others expected to launch. Positive results for mirikizumab and TREMFYA were reported in 2024, and Dong-A-ST's Imuldosa received FDA approval as a biosimilar to Stelara.

Xiaorong He, Boehringer Ingelheim's senior VP, discusses AI's role in pharma, highlighting investments in AI-based tech, partnerships with Ten63, Phenomic AI, Google Quantum AI, and IBM. AI applications span drug discovery to clinical trials, aiming to enhance success rates and streamline processes, with examples like ADAM and IQNow. Future AI in pharma is expected to boost productivity, speed, and resource utilization, with ongoing initiatives in sustainability and patient-centricity.